SCHEMBL880275

SCHEMBL880275

O=C1CC(c2ccc(Cl)cc2)c2cc(-c3ccccc3)ccc2N1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.57
LMNA P02545 2/20 0.46
PGR P06401 3/20 0.45
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
THRB P10828 1/20 0.43
GPBAR1 Q8TDU6 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
CNR1 P21554 1/20 0.41
NTSR1 P30989 1/20 0.41
OPRK1 P41145 1/20 0.41
PDE4D Q08499 1/20 0.41
ATM Q13315 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10280613 0.90 TP53 (0.57) TP53LMNAPGRMAPTSMN1; SMN2
SCHEMBL880483 0.88 LMNA (0.62) TP53LMNAPGRMAPTSMN1; SMN2
SCHEMBL880444 0.82 TP53 (0.59) TP53LMNAMAPTSMN1; SMN2THRB
SCHEMBL880446 0.80 KMT2A (0.48) TP53LMNAMAPTSMN1; SMN2THRB
SCHEMBL7701639 0.79 TP53 (0.51) TP53LMNAMAPTGPBAR1SIRT2
SCHEMBL10280718 0.79 LMNA (0.63) TP53LMNAPGRMAPTSMN1; SMN2
SCHEMBL6863006 0.78 TP53 (0.50) TP53LMNAMAPTSMN1; SMN2GPBAR1
SCHEMBL880285 0.75 BRD4 (0.47) TP53LMNAMAPTSMN1; SMN2GPBAR1
SCHEMBL10280719 0.74 TP53 (0.45) TP53LMNAMAPTSMN1; SMN2GPBAR1
SCHEMBL12559670 0.74 TDP1 (0.57) TP53LMNASMN1; SMN2THRBSIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT TP53 1529/4885LMNA 525/4885PGR 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.